<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-4-1.anc" start="23063" end="23074" sStart="-1" offset="0" sid="null" wn="2" wnkey="transfer%2:40:01::" annotator="carichter" text="Because binding of cell-surface receptors to polyethylenimine filters is rather insensitive to ionic strength, the ionic phenomenon is thought to be supplemented by hydrophobic &lt;b&gt;forces&lt;/b&gt; and hydrogen binding [ 32 ] . The method used with Y-79 cells and radiolabeled PEDF has been described before in detail [ 18 ] . Briefly, cells cultured overnight in serum-deprived medium at 37¡C were &lt;b&gt;transferred&lt;/b&gt; to ice/water bath for 10 minutes before the addition of ligand." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-4-1.anc" start="24543" end="24554" sStart="null" offset="0" sid="null" wn="3 2" wnkey="null" annotator="carichter" text="Each Microcon retenate cup was &lt;b&gt;transferred&lt;/b&gt; to scintillation vials, mixed with 5 ml BioSafe II liquid scintillation solution (Research Products International) by extensive vortexing, and its radioactivity determined using a ?-scintillation counter." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2091-4-1.anc" start="14816" end="14826" sStart="null" offset="177" sid="r8.suggest.v.0737" wn="3" wnkey="suggest%2:32:02::" annotator="veweser" text="In this regard, we observed that depletion from the Y-79 cell cultures of heparin with heparinase was lower than those depleted of HS with heparitinase, suggesting that the retinoblastoma-derived HS was more effective than the retinoblastoma-derived heparin." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-4-1.anc" start="16670" end="16674" sStart="null" offset="0" sid="null" wn="1" wnkey="lose%2:40:02::" annotator="veweser" text="Finally, the fact that the GAG and receptor binding regions are on opposite regions of the PEDF molecule, suggest the possibility of the existence of PEDF mutants or engineered variants that, having &lt;b&gt;lost&lt;/b&gt; or decreased GAG-binding capabilities, still show high affinity for the PEDF receptor in a way not dependent upon GAGs content or composition." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-4-1.anc" start="16670" end="16674" sStart="null" offset="0" sid="null" wn="1" wnkey="lose%2:40:02::" annotator="veweser" text="Finally, the fact that the GAG and receptor binding regions are on opposite regions of the PEDF molecule, suggest the possibility of the existence of PEDF mutants or engineered variants that, having &lt;b&gt;lost&lt;/b&gt; or decreased GAG-binding capabilities, still show high affinity for the PEDF receptor in a way not dependent upon GAGs content or composition." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-4-1.anc" start="16670" end="16674" sStart="null" offset="0" sid="null" wn="1" wnkey="lose%2:40:02::" annotator="tofox" text="Finally, the fact that the GAG and receptor binding regions are on opposite regions of the PEDF molecule, suggest the possibility of the existence of PEDF mutants or engineered variants that, having &lt;b&gt;lost&lt;/b&gt; or decreased GAG-binding capabilities, still show high affinity for the PEDF receptor in a way not dependent upon GAGs content or composition." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-4-1.anc" start="16670" end="16674" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="jeneale" text="Finally, the fact that the GAG and receptor binding regions are on opposite regions of the PEDF molecule, suggest the possibility of the existence of PEDF mutants or engineered variants that, having &lt;b&gt;lost&lt;/b&gt; or decreased GAG-binding capabilities, still show high affinity for the PEDF receptor in a way not dependent upon GAGs content or composition." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-4-1.anc" start="16670" end="16674" sStart="null" offset="0" sid="null" wn="1" wnkey="lose%2:40:02::" annotator="comcgeetubb" text="Finally, the fact that the GAG and receptor binding regions are on opposite regions of the PEDF molecule, suggest the possibility of the existence of PEDF mutants or engineered variants that, having &lt;b&gt;lost&lt;/b&gt; or decreased GAG-binding capabilities, still show high affinity for the PEDF receptor in a way not dependent upon GAGs content or composition." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-4-1.anc" start="16670" end="16674" sStart="null" offset="0" sid="null" wn="8" wnkey="lose%2:40:00::" annotator="cgozo" text="Finally, the fact that the GAG and receptor binding regions are on opposite regions of the PEDF molecule, suggest the possibility of the existence of PEDF mutants or engineered variants that, having &lt;b&gt;lost&lt;/b&gt; or decreased GAG-binding capabilities, still show high affinity for the PEDF receptor in a way not dependent upon GAGs content or composition." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-4-1.anc" start="16670" end="16674" sStart="null" offset="0" sid="null" wn="1" wnkey="lose%2:40:02::" annotator="brubin" text="Finally, the fact that the GAG and receptor binding regions are on opposite regions of the PEDF molecule, suggest the possibility of the existence of PEDF mutants or engineered variants that, having &lt;b&gt;lost&lt;/b&gt; or decreased GAG-binding capabilities, still show high affinity for the PEDF receptor in a way not dependent upon GAGs content or composition." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-4-1.anc" start="16670" end="16674" sStart="null" offset="0" sid="null" wn="1" wnkey="lose%2:40:02::" annotator="brubin" text="Finally, the fact that the GAG and receptor binding regions are on opposite regions of the PEDF molecule, suggest the possibility of the existence of PEDF mutants or engineered variants that, having &lt;b&gt;lost&lt;/b&gt; or decreased GAG-binding capabilities, still show high affinity for the PEDF receptor in a way not dependent upon GAGs content or composition." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-4-1.anc" start="16670" end="16674" sStart="null" offset="0" sid="null" wn="1" wnkey="lose%2:40:02::" annotator="a4" text="Finally, the fact that the GAG and receptor binding regions are on opposite regions of the PEDF molecule, suggest the possibility of the existence of PEDF mutants or engineered variants that, having &lt;b&gt;lost&lt;/b&gt; or decreased GAG-binding capabilities, still show high affinity for the PEDF receptor in a way not dependent upon GAGs content or composition." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-4-1.anc" start="16670" end="16674" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="a3" text="Finally, the fact that the GAG and receptor binding regions are on opposite regions of the PEDF molecule, suggest the possibility of the existence of PEDF mutants or engineered variants that, having &lt;b&gt;lost&lt;/b&gt; or decreased GAG-binding capabilities, still show high affinity for the PEDF receptor in a way not dependent upon GAGs content or composition." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-4-1.anc" start="16670" end="16674" sStart="null" offset="0" sid="null" wn="1" wnkey="lose%2:40:02::" annotator="a2" text="Finally, the fact that the GAG and receptor binding regions are on opposite regions of the PEDF molecule, suggest the possibility of the existence of PEDF mutants or engineered variants that, having &lt;b&gt;lost&lt;/b&gt; or decreased GAG-binding capabilities, still show high affinity for the PEDF receptor in a way not dependent upon GAGs content or composition." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-4-1.anc" start="16670" end="16674" sStart="null" offset="0" sid="null" wn="1" wnkey="lose%2:40:02::" annotator="a1" text="Finally, the fact that the GAG and receptor binding regions are on opposite regions of the PEDF molecule, suggest the possibility of the existence of PEDF mutants or engineered variants that, having &lt;b&gt;lost&lt;/b&gt; or decreased GAG-binding capabilities, still show high affinity for the PEDF receptor in a way not dependent upon GAGs content or composition." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2091-4-1.anc" start="17918" end="17922" sStart="null" offset="175" sid="r10.high.j.0930" wn="1" wnkey="high%3:00:02::" annotator="anfahmy" text="Our data suggest that the intrinsic affinity of the cell surface receptor for PEDF appears low, whereas the heparin/HS-PEDF complex is recognized with high affinity." />
  </sentences>
</list>